Background: Imatinib, a tyrosine kinase inhibitor, causes growth failure in children with chronic myeloid leukemia probably by targeting the growth hormone (GH)/insulin like growth factor-1 (IGF-1) axis. Here, IGF1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.